Qualigen Therapeutics Reports $1.7 Million Net Loss and Increased Financial Challenges in Latest Filing

Qualigen Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of $1.7 million for the three months ended June 30, 2025, compared to a loss of $1.6 million for the same period in 2024. For the six months ending June 30, 2025, the net loss increased to $4.3 million, up from $3.6 million in the prior year. The total expenses for the second quarter were approximately $1.7 million, a slight decrease from $1.74 million in the previous year, while total expenses for the first half of 2025 reached $4.4 million, compared to $3.2 million in 2024.

The company experienced a notable increase in general and administrative expenses, which rose by 38% to $1.4 million in the second quarter, primarily due to higher professional fees and consulting costs associated with fundraising efforts. Conversely, research and development expenses plummeted by 98% to $18,000, reflecting a strategic slowdown in development activities. Additionally, Qualigen recorded a credit loss expense of $271,000 related to short-term notes receivable, marking a significant shift from the previous year when no such expense was reported.

Qualigen's operational metrics indicate a challenging environment, with cash and cash equivalents decreasing to approximately $332,000 as of June 30, 2025, down from $1.2 million at the end of 2024. The company’s accumulated deficit has now reached $127.4 million. Current liabilities surged to $5.6 million, primarily due to the issuance of short-term debt and promissory notes. The company has engaged in multiple financing activities, including raising $3.6 million from short-term borrowings and an additional $4.3 million from a private placement in July 2025, which it expects will provide liquidity through the end of the year.

Strategically, Qualigen has been focusing on its lead therapeutic program, QN-302, and a co-development agreement with Marizyme, Inc. for the DuraGraft vascular conduit solution. However, the company has indicated that it will continue to face liquidity challenges and expects to incur further losses. The management has acknowledged the need for additional funding to support its operations and development plans, raising substantial doubt about its ability to continue as a going concern over the next year.

Looking ahead, Qualigen's management is reviewing its strategic options to advance its therapeutics pipeline while implementing cost controls to mitigate losses. The company has not provided specific timelines for product development but has indicated that it will ramp up activities once adequately funded. The ongoing geopolitical tensions and inflationary pressures may also impact the company's operational environment, further complicating its financial outlook.